Leptomeningeal metastasis: A Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials

Neuro-Oncology

Volumn 16, Issue 9, 2014, Pages 1176-1185

  Chamberlain, Marc ^a   Soffietti, Riccardo ^b   Raizer, Jeffrey ^c   Rudà, Roberta ^b   Brandsma, Dieta ^d   Boogerd, Willem ^d   Taillibert, Sophie ^e   Groves, Morris D ^f   Le Rhun, Emilie ^g,h   Junck, Larry ^b   Van Den Bent, Martin ^b   Wen, Patrick Y ⁱ   Jaeckle, Kurt A ^j  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f TEXAS ONCOLOGY   (United States)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; METHOTREXATE; THIOTEPA;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL EXAMINATION; DRUG EFFICACY; HUMAN; LEPTOMENINGEAL METASTASIS; MENINGEAL METASTASIS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEUROIMAGING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZATION; STUDY DESIGN; SYSTEMIC THERAPY; TREATMENT RESPONSE; BIOASSAY; MENINGEAL NEOPLASMS; PHASE 2 CLINICAL TRIAL (TOPIC); SECONDARY; STANDARDS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; ENDPOINT DETERMINATION; HUMANS; MENINGEAL NEOPLASMS; PATIENT OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84906995462     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou089     Document Type: Review

References (51)

1. Chamberlain MC. Leptomeningeal metastases. Curr Opin Oncol. 2010;22(6):627-635.
2. Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis, and treatment. Semin Oncol. 2006;33(3):312-323. (Pubitemid 43849934)
3. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9(3):225-229.
4. Pace P, Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol. 2006;60(3):528-534.
5. Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369-1375. (Pubitemid 9256272)
6. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5(5):443-452.
7. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759-772. (Pubitemid 12165435)
8. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53(7):626-632. (Pubitemid 26242213)
9. van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology. 1999;53(2):382-385. (Pubitemid 29344363)
10. Chamberlain MC. Neoplastic meningitis in Neuro-Oncology. In: Grisold W, Soffietti R, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier; 2012;105:757-766.
11. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998;38(2-3):245-252. (Pubitemid 28306215)
12. Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 2009;93(2):205-212.
13. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003;21(1):25-66. (Pubitemid 36169344)
14. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neuro Oncol. 1995;23(3):233-238.
15. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51-57.
16. Clarke JL, Perez HR, Jacks LM, et al. Leptomeningeal metastasis in the MRI era. Neurology. 2010;74(18):1449-1454.
17. Pauls S, Fischer AC, Brambs HJ, et al. Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors. Eur J Radiol. 2012;81(5):974-978.
18. Chamberlain MC. Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncology. 2013;2(2):121-128.
19. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733-739. (Pubitemid 28090286)
20. Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology. 1998;50(4):1173-1175. (Pubitemid 28212864)
21. Walbert T, Groves MD. Known and emerging biomarkers for leptomeningeal metastasis and its response to treatment. Future Oncol. 2010;6(2):287-297.
22. Lin N, Dunn IF, Glantz M, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg. 2011;115(4):730-736.
23. Chamberlain MC, Junck L. Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated? Expert Rev Neurother. 2004;4(4 Suppl):S3-S10.
24. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161-166.
25. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neuro Oncol. 1998;38(2-3):151-157. (Pubitemid 28306202)
26. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561-1567. (Pubitemid 28175781)
27. Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol. 2006;78(3):255-260. (Pubitemid 44018818)
28. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46(6):1674-1677.
29. Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54(11):1364-1368. (Pubitemid 27469350)
30. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neuro Oncol. 1998;38(2-3):135-140. (Pubitemid 28306199)
31. Grossman SA, Trump CL, Chen DCP, et al. Cerebrospinal flow abnormalities in patients with neoplastic meningitis. Am J Med. 1982;73(5):641-647.
32. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5(10):1655-1662. (Pubitemid 18010143)
33. Glantz MJ, Van Horn A, Fisher R, et al. Route of intra-cerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116(8):1947-1952.
34. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11(3):561-569. (Pubitemid 23071056)
35. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110-3116. (Pubitemid 29470639)
36. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402.
37. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40(18):2726-2733. (Pubitemid 39574724)
38. Shapiro WR, Schmid M, Glantz M, et al. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol. 2006;24:(June 6 suppl):1528s (abstr).
39. Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12(November):21-25.
40. Patel AS, Allen JE, Dicker DT, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752-760.
41. Nayak L, Fleisher M, Gonzalez-Espinosa R, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastaseis in slide tumors. Neurology. 2013;80(17):1598-1605.
42. Vincent A, Lesger G, Brown D, et al. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer. 2013;16(1):122-126.
43. Stapleton S, Blaney SM. New agents for intrathecal administration. Cancer Invest. 2006;24(5):528-534. (Pubitemid 44576407)
44. Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 2008;10(2):208-215.
45. Chamberlain MC, Wei-Tao DD, Groshen S. A phase 2 trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106(9):2021-2027. (Pubitemid 43673219)
46. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005;23(7):1555-1563.
47. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350-1356. (Pubitemid 46706881)
48. Rubenstein JL, Chen L, Advani R, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745-751.
49. Chamberlain MC. Alpha-interferon in the treatment of neoplastic meningitis. Cancer. 2002;94(10):2675-2680.
50. Chamberlain MC, Johnston S, Van Horn A, et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol. 2009;91(3):271-277.
51. Mir O, Ropert S, Alexandre J, et al. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008;19(11):1978-1980.